Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes... Read more »
[Updated, 9:20 a.m. ET, see below] Biogen has seen its highest highs under CEO George Scangos, but some lows too. After a year in which Biogen’s share price has... Read more »
Relypsa got a big boost in May when a rival stumbled. Now it’s being rewarded with a buyout offer worth close to three times the price it went public at in... Read more »
As the possibility of the first ever gene therapy approval in the U.S. draws closer, more gene therapy players are entering the public markets. Today, it’s San Francisco’s Audentes Therapeutics, which... Read more »
Zafgen’s prospects have been unclear ever since two patients died in a Phase 3 trial of its lead drug candidate, beloranib, a potential treatment for obesity in patients with a rare... Read more »
The field of cancer immunotherapy is so crowded and competitive these days that many companies are trying to stand by touting a next-generation approach. The latest company to do so is Oncorus, a... Read more »
Former Epizyme CEO Robert Gould is back with a new startup. A year after stepping down as the CEO of Cambridge, MA-based Epizyme, Gould has re-emerged to lead another Cambridge company,... Read more »
Inside our bodies, our cells move around, communicate, form new tissue, and heal wounds with the help of proteins called integrins. But when disease occurs, integrins get the wrong cues and... Read more »
Syros Pharmaceuticals has a long way to go before it knows whether its drug discovery work will pay off. But insiders and Wall Street investors have given the firm’s efforts a... Read more »
Moderna Therapeutics still hasn’t produced data in humans supporting its technology, which is meant to turn our bodies into little drugmaking factories. But the Cambridge, MA-based company nonetheless keeps grabbing the... Read more »
The outlook for Infinity Pharmaceuticals didn’t look good after its blood cancer drug, duvelisib, came up short in a critical clinical trial a few weeks ago, and the situation has gotten... Read more »
A new wave of drugs has changed the way hepatitis C is treated. Regulus Therapeutics has not been part of that wave, but the company’s plans to join it took a... Read more »
Waltham, MA-based Forum Pharmaceuticals, which spent more than decade pursuing a drug for Alzheimer’s and other neurological diseases, is shutting down, Xconomy has learned.
According to a Forum spokesperson, the company... Read more »
It’s a week for the history books. The United Kingdom voted to leave the European Union last night, triggering worldwide financial fears and, perhaps, a breakup of the U.K. itself. Closer... Read more »
Engineered organ developer Harvard Apparatus Regenerative Technology has done all it can to disassociate itself from the surgeon Paolo Macchiarini. The Holliston, MA-based company is now known as Biostage (NASDAQ: BSTG... Read more »
Because public investors have had a more discerning attitude toward biotech IPOs this year, insiders have had to step up to help their companies go public. One extreme example is Selecta... Read more »
There is no shortage of companies out there trying to tweak our immune systems in one way or another to treat diseases like cancer. Today, IFM Therapeutics, a new startup seeded... Read more »
Paratek Pharmaceuticals has stuck with its antibiotic omadacycline over the years, even as three of the company’s pharmaceutical partners bailed on the drug. Today the Boston company has taken a key... Read more »
It wasn’t too long ago that Aegerion Pharmaceuticals seemed to be a successful biotech turnaround story with its first drug on the market and optimism ahead. But just a few short... Read more »
October 27, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.